RE:RE:RE:RE:Possible chinese partner?This is the opposite of what is usually seen, a US established company licensing in China drug form an upstart. Usually it's the opposite. But shows that you likely need to find partners to ramp up sales quickly until such time a new therapy comes along and unseats you. It's an NPV game so you go for it with partnerships to build large sales as quickly as possible.
It's an interesting case. RemeGens target is HER2+ and they must have proven up the concept a while back as once they got the China approval and FDA fasttrack they already had around 15 clinical studies listed in the database for various indicatinons all HER2+. They were also in all phases --some 1a, some 1b and some Phase 2. That seems to be the model -- if your target works, quickly identify the short list of the most effective cancers and go for them with specific trials and then partner with others in some of the smaller, peripheral or complex ones where someone else has superior and more advanced in=house skill. But given there are 15 of them in trial now for RemeGen, they must have been at it a while.
If we see this POC around sortilin and the platform, these are the kind of good, but problematic, issues you would face. You definitely would need at least $10mil for each indication to just get it up and running I would think. Another reason for the larger shelf offering being updated. I just hope the newsflow is positive enough they get a fair valuation and can raise $150mil, have the bond convert, and put together a program large in breadth like we've seen some of these other platforms do.
scarlet1967 wrote: There are not many targeted delivery drugs (ADC/PDC) currently approved or in clinical trial stages, there are currently 11 approved ADCs and one PDC. The company mentioned it was some interest for their PDC in China but even Chinese companies with promising targeted delivery drugs get snapped up but bigger companies for instance Seagen with market value $28B almost $2b cash on their balance sheet grasped RemeGen’s ADC last August.
“Under the terms of the agreement, Seagen will make $200 million upfront payment to exclusively license rights to disitamab vedotin for global development and commercialization, outside of RemeGen’s territory. Seagen will pay RemeGen up to $2.4 billion in potential total milestone payments based upon the achievement of specified development, regulatory and commercialization goals across multiple indications and products. RemeGen will be entitled to a tiered, high single digit to mid-teen percentage royalty based on net sales of disitamab vedotin in Seagen’s territory.”
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin | Business Wire RemGen has a market value at $4B and their main drugs are the ADC above conditionally approved in China and a drug for auto immune diseases also conditionally approved in China both in the first half of 2021 so this deal was a big one for this company.
Point is in terms of availability there are not many deal candidates for cash rich companies in targeted delivery space so even Chinese companies with promising drugs are targeted by international big pharmas so if and when THTX’s PDC shows promising results they will be not only Chinese companies but also many other international companies who will be interested in their drug. Now Sutro decided to pull the trigger as early as the end of phase1a with smaller upfront payment, royalties etc. compared to RemGen’s drug currently approved in China and in Phase2 stage in the US.
So decent results from phase1a and beyond can open up opportunities for THTX to start collaborations with international and Chinese companies. I just hope the new “deal maker” director and the CFO have the skill set to put together a decent partnership contract.
palinc2000 wrote: Levesque meentioned that there was Chinese interest in the Sort1 platform.CStone Parmaceuticals has a market cap over 5 times that of THTX and seems it could be a good fit ....
Bucknelly21 wrote: I think it's impossible at this point with the lack of information Thtx has given to make any meaningful guess at what's going on...